leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...8384858687888990919293...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Exploration of a novel HRD signature (HRDsig) as a biomarker of first line FOLFIRINOX benefit in metastatic pancreatic cancer (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_2209;    
    FOLFIRINOX (FX) or gemcitabine with albumin-bound paclitaxel (GP) are standard in the first line (1L) setting, though no biomarkers are available to guide therapy selection...Conclusions Using a real-world clinical dataset, we found that HRDsig positivity was predictive of FX benefit in metastatic PC. Additional studies are warranted to further explore the utility of this biomarker.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
    Duration of adjuvant therapy in stage III colon cancer: A real world multi-institutional US-based experience (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_2157;    
    AEs were more prevalent in US pts compared to non-US pts in IDEA, likely due to capecitabine intolerance. Our study is the first to assess 3mo vs 6mo capecitabine based adjuvant CTX in a risk stratified US population and suggests discrepancies in DFS and AEs compared to IDEA in US pts who received CAPOX.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_2055;    
    Methods 3'RNAseq was performed in 1,734 FFPE samples from the PETACC8 trial including patients with stage III CC and treated with FOLFOX +/- cetuximab...Our study paves the way towards personalized care according to the estimation of this risk of recurrence, especially for the decision of adjuvant chemotherapy. Table: 321P The predictive model
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_1998;    
    P2
    Background The benefit of adding the antiangiogenic drug aflibercept to FOLFIRI regime in metastatic colorectal cancer (CRC) patients resistant to or progressive on an oxaliplatin-based therapy have been previously demonstrated...Moreover, the combination of circulating VEGF-A and miR-33b-5p levels improved clinical stratification of metastatic CRC patients who were to receive FOLFIRI plus aflibercept treatment. Conclusions In conclusion, our study supports circulating miRNAs as valuable biomarkers for predicting better outcomes in metastatic CRC patients treated with FOLFIRI plus aflibercept.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma: A single center experience (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_1977;    
    Although the first-line of treatment for metastatic SCAC (mSCAC) is better codified with two validated treatment regimens, carboplatin-paclitaxel and modified DCF (docetaxel-cisplatin-5FU), there is no consensus regarding subsequent lines...Metastatic SCAC is a quite rare pathology with few approved treatment lines. Therefore, patients with mSCAC need more therapeutic options, including treatments already well known in other localizations and innovative treatments.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST) (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_1966;    
    Background FOLFIRI plus bevacizumab (BEV) is widely used as first-line treatment for metastatic colorectal cancer (mCRC), and FOLFOXIRI plus BEV is an option...In arm A, patients received FOLFIRI (irinotecan [IRI] 180 mg/m 2 , l-leucovorin [l-LV] 200 mg/m 2 , bolus 5-fluorouracil [5-FU] 400 mg/m 2 , continuous 5-FU 2400 mg/m 2 ) plus RAM (8 mg/kg) biweekly until disease progression...Major grade >3 adverse events (incidence in arm A/B) were neutropenia (44.1/72.6%), hypertension (15.3/19.4%), proteinuria (13.6/12.9%), anorexia (3.4/14.5%), febrile neutropenia (3.4/11.3%), and diarrhea (1.7/8.1%). Conclusions FOLFOXIRI plus RAM did not show significant superiority in terms of ORRs and PFS compared with FOLFIRI plus RAM as first-line treatment for mCRC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_1885;    
    P2
    Overall, FOLFIRI + cetuximab could be reintroduced in 74% of pts, and ≥ 2 times in 21% of pts in arm A and 36% in arm B. In an exploratory multivariate analysis, the two significant prognostic factors for PFS were treatment arm and primary tumor site, and platelet count and primary tumor site for OS. Table: 387P Results according to centralized RAS and BRAF status Conclusions Although the cetuximab maintenance arm did not meet the primary objective, a clinically meaningful difference in PFS and OS in favor of cetuximab maintenance was found in pts with RAS/BRAF wt mCRC.
  • ||||||||||  Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
    Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jul 28, 2022   
    P1,  N=12, Not yet recruiting, 
    Secondary endpoints include magrolimab concentration vs time, antidrug antibodies (safety run-in), objective response rate, PFS by independent central review, duration of response, and overall survival (ph2). Trial completion date: Jun 2023 --> Jun 2024 | Initiation date: Jan 2022 --> Dec 2022 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  BOLD-100 / Bold Therap
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  BOLD-100-001: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours (clinicaltrials.gov) -  Jul 28, 2022   
    P1b,  N=80, Recruiting, 
    Trial completion date: Jun 2023 --> Jun 2024 | Initiation date: Jan 2022 --> Dec 2022 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Mar 2022 --> Jan 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Opdivo (nivolumab) / BMS
    New P2 trial:  LOGICAN: Oxaliplatin  (clinicaltrials.gov) -  Jul 27, 2022   
    P2,  N=118, Not yet recruiting, 
  • ||||||||||  irinotecan / Generic mfg.
    Enrollment open:  sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) (clinicaltrials.gov) -  Jul 27, 2022   
    P2,  N=38, Recruiting, 
    Based on our findings, the safety and efficacy of mFOLFIRINOX (irinotecan 80 mg/m) in DV patients were comparable with the standard mFOLFIRINOX (irinotecan 150 mg/m) in non-DV patients. Not yet recruiting --> Recruiting
  • ||||||||||  leucovorin calcium / Generic mfg., pyrimethamine / Generic mfg.
    Review, Journal:  Congenital Toxoplasmosis: The State of the Art. (Pubmed Central) -  Jul 27, 2022   
    When congenital infection is evident, disease include retinochoroiditis, cerebral calcifications, hydrocephalus, neurocognitive impairment. The diagnosis of congenital infection must be confirmed at birth and management, specific therapy, and follow-up with multidisciplinary counseling, must be guaranteed.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Trial primary completion date:  NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (clinicaltrials.gov) -  Jul 26, 2022   
    P1,  N=24, Recruiting, 
    These were found to be entire molecular targets affecting the cancer progression and metastasis as well as the NACT effectiveness. Trial primary completion date: Oct 2022 --> Oct 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC) (7.3.G - Grenoble Auditorium) -  Jul 25, 2022 - Abstract #ESMO2022ESMO_1688;    
    P2, P3
    In the Ph 2 ANCHOR study (NCT03693170), mPFS was 5.8 mo and ORR was 48% with 1L EC + binimetinib in BRAF V600E mCRC...Pts previously treated with BRAFi/EGFRi or both oxaliplatin and irinotecan were excluded...Conclusions EC + chemo was generally tolerable. Preliminary promising antitumor activity was seen in 1L and 2L BRAF V600E mCRC, supporting the ongoing study.
  • ||||||||||  cirtuvivint (SM08502) / Biosplice Therap
    Preliminary evidence of clinical activity from phase I and Ib trials of the CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors (7.3.O - Orléans Auditorium) -  Jul 25, 2022 - Abstract #ESMO2022ESMO_1519;    
    P1, P1b
    The phase Ib study combines CIRT with abiraterone acetate, FOLFIRI-panitumumab, or docetaxel in advanced/metastatic CRPC, CRC, and NSCLC, respectively...In the phase Ib combination study, in CRPC subjects that would be considered hormonal therapy resistant, we observed 2 PSA50s and 2 PSA30s among 5 subjects treated with at least 2 cycles of therapy. Conclusions Findings from these 2 studies provide evidence of clinical activity with manageable toxicity for CIRT in an advanced cancer patient population and suggest hormonal therapy resistance can be overcome in CRPC subjects when CIRT is combined with abiraterone acetate.